Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Other Accumulated Expenses (2021 - 2025)

Nutex Health's Other Accumulated Expenses history spans 5 years, with the latest figure at $49.7 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 4.19% year-over-year to $49.7 million; the TTM value through Dec 2025 reached $49.7 million, up 4.19%, while the annual FY2025 figure was $49.7 million, 4.19% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $49.7 million at Nutex Health, down from $64.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $68.8 million in Q2 2025 and bottomed at $6.2 million in Q4 2022.
  • The 5-year median for Other Accumulated Expenses is $20.6 million (2024), against an average of $27.7 million.
  • The largest annual shift saw Other Accumulated Expenses tumbled 73.62% in 2022 before it surged 193.74% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $6.9 million in 2021, then fell by 9.08% to $6.2 million in 2022, then soared by 136.72% to $14.8 million in 2023, then skyrocketed by 223.16% to $47.7 million in 2024, then grew by 4.19% to $49.7 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Other Accumulated Expenses are $49.7 million (Q4 2025), $64.3 million (Q3 2025), and $68.8 million (Q2 2025).